Human Papillomavirus clinical trials

Explore recruiting human papillomavirus clinical trials.

Recruiting human papillomavirus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Human Papillomavirus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age

Germany, Czechia, Italy, France, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2)

Netherlands, Belgium, Czechia, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Developing a first-void urine-based infection model to study HPV-specific antibody-virion interaction before and after vaccination with the Gardasil-9 HPV vaccine – a non-randomized open-label study.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, placebo-controlled, double-blind study to evaluate 2LPAPI® efficacy on the clearance of genital HR-HPV infections (PAPION study)

Belgium, Romania

Therapeutic use (Phase IV) EU CTIS Study details

HPV2-2303 - Phase 2 clinical trial evaluating secondary HPV vaccination after treatment of high-grade cervical lesions

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Human Papillomavirus trials by city

Human Papillomavirus in Toronto Human Papillomavirus in Vancouver Human Papillomavirus in Montreal Human Papillomavirus in Calgary Human Papillomavirus in Edmonton Human Papillomavirus in Ottawa Human Papillomavirus in Winnipeg Human Papillomavirus in Quebec City Human Papillomavirus in Hamilton Human Papillomavirus in Kitchener Human Papillomavirus in London Human Papillomavirus in Halifax Human Papillomavirus in New York Human Papillomavirus in Los Angeles Human Papillomavirus in Chicago Human Papillomavirus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease